US Patent

US8778394 — Small-volume oral transmucosal dosage forms

Method of Use · Assigned to AcelRx Pharmaceuticals Inc · Expires 2027-01-05 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects small-volume oral transmucosal dosage forms, such as NanoTabs, for administering a drug for treating acute, post-operative, or breakthrough pain.

USPTO Abstract

Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1351 — sufentanil-citrate

Patent Metadata

Patent number
US8778394
Jurisdiction
US
Classification
Method of Use
Expires
2027-01-05
Drug substance claim
No
Drug product claim
No
Assignee
AcelRx Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.